<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03183505</url>
  </required_header>
  <id_info>
    <org_study_id>AYPB-MDD-Ⅱb-1701</org_study_id>
    <secondary_id>2017ZX09304-020</secondary_id>
    <nct_id>NCT03183505</nct_id>
  </id_info>
  <brief_title>Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb</brief_title>
  <official_title>Safety and Efficacy Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Ⅱb Stratified Randomized, Double-Blind, Placebo-Paralleled, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Su Zhou YiHua Biotechnology Co. LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Anyu Peibo Capsule&#xD;
      comparing with placebo in the treatment of Chinese Patients with Depression. And to provide&#xD;
      some scientific evidence for protocol designing in following phase Ⅲ clinical trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2017</start_date>
  <completion_date type="Actual">November 29, 2018</completion_date>
  <primary_completion_date type="Actual">October 5, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change of total score from baseline in MADRS scale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate according to MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission Rate according to MADRS</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Response Rate according to HAMD-17</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission Rate according to HAMD-17</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Change of CGI (CGI-S, CGI-I) from baseline</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Change of total score from baseline in HAMA</measure>
    <time_frame>6 weeks</time_frame>
    <description>Hamilton Anxiety Rating Scale</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Physical Examination</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AE</measure>
    <time_frame>6 weeks</time_frame>
    <description>Adverse Events</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory Examination</measure>
    <time_frame>6 weeks</time_frame>
    <description>Blood RT, Urinalysis, Hepatic function, Renal function, FBG, Lipid, CK, Thyroid Function Test and Serum-HCG(fertile women only)</description>
  </other_outcome>
  <other_outcome>
    <measure>the Change of ECG from baseline</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Anyu Peibo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anyu Peibo Capsule, oral, 0.8g twice per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo,oral, twice per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anyu Peibo</intervention_name>
    <description>Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper</description>
    <arm_group_label>Anyu Peibo</arm_group_label>
    <other_name>Anyu Peibo Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Capsule, twice per day, oral after breakfast and supper</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult with primary diagnosis of major depressive disorder(MDD) based on the criteria&#xD;
             of DSM-5, single episode or recurrent episode.&#xD;
&#xD;
          -  The total score of MADRS is ≥24 in both screening visit and baseline visit.&#xD;
&#xD;
          -  The total score of HAMD-17 is ≥18 and the first item (depressed mood) is ≥2 in both&#xD;
             screening visit and baseline visit.&#xD;
&#xD;
          -  CGI-S is ≥4 in both screening visit and baseline visit.&#xD;
&#xD;
          -  The subject understands and consents to takes part in this clinical trials. The&#xD;
             subjects should sign informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a suicide attempt within recent 1 year, or has a currently significant&#xD;
             risk of suicide, or has a score ≥3 on item 3(suicide assessment) of the HAMD.&#xD;
&#xD;
          -  The subject has a current psychiatric diagnosis other than depression.&#xD;
&#xD;
          -  When the HAMD-17 score of baseline visit compares with the screening visit, the&#xD;
             decreasing rate is ≥25%.&#xD;
&#xD;
          -  Known hypersensitivity to Big Leaf Ju, or at least to two kinds of drugs.&#xD;
&#xD;
          -  Any unstable cardiovascular, hepatic, renal, blood, endocrine, or other medical&#xD;
             disease.&#xD;
&#xD;
          -  Any neurological disease (such as Parkinson's Disease, cerebrovascular accident and&#xD;
             epilepsy) or cerebral injury (traumatic or disease related).&#xD;
&#xD;
          -  Had a history or a high risk related disease or medication of seizure disorder,except&#xD;
             infantile febrile convulsion.&#xD;
&#xD;
          -  Had a history of hyperthyroidism or hypothyroidism within recent 1 year and still&#xD;
             taking medication.&#xD;
&#xD;
          -  With psychotic symptoms.&#xD;
&#xD;
          -  The subject has a history of mania episode, including manic, mixed, bipolar depression&#xD;
             or rapid cycle attack.&#xD;
&#xD;
          -  The subject has a current diagnosis of depression due to a somatic disease.&#xD;
&#xD;
          -  The subject could not take medication or has a disease affecting drug absorption, such&#xD;
             as active bowel disease, partial or total intestinal obstruction, or chronic diarrhea.&#xD;
&#xD;
          -  Clinically significant electrocardiographic(ECG) abnormalities in screening visit.&#xD;
             Such as QTc ≥450 ms in male or ≥470 ms in female; Sinus bradycardia and HR ≤ 50 bpm; Ⅲ&#xD;
             atrioventricular block; atrial fibrillation, etc.&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values(eg. Routine blood value above or&#xD;
             below 1.2 times of the normal range; urine WBC, RBC or protein ≥++; ALT or AST value&#xD;
             above 1.5 times of clinical top-limit; BUN value above 1.2 times of top-limit; Cr&#xD;
             value above normal top-limit; thyroid gland function index above or below 1.2 times of&#xD;
             the normal range, Fasting plasma glucose value above 1.2 times of normal top-limit;&#xD;
             blood fat value above 1.5 times of normal top-limit).&#xD;
&#xD;
          -  The subject who used at least two different antidepressants with recommended dose and&#xD;
             adequate duration (maximum dosage by at least 4 weeks according to label) treatment&#xD;
             still had no respond.&#xD;
&#xD;
          -  The subject uses antidepressant drug normally before 2 weeks of screening, and stops&#xD;
             using psychotropic drug before randomization less than 7 half-life period (monoamine&#xD;
             oxidase inhibitor: at least 2 weeks; fluoxetine: at least 1 month)&#xD;
&#xD;
          -  The subject received light therapy within 2 weeks.&#xD;
&#xD;
          -  The subject received ECT, trans-cranial magnetic stimulation, or other physics therapy&#xD;
             within 3 months.&#xD;
&#xD;
          -  The subject received systematic psychotherapy (interpersonal relationship,&#xD;
             psychoanalytic therapy, or cognitive behavioral therapy) within 3 months or plan to&#xD;
             use systematic psychotherapy during the study period.&#xD;
&#xD;
          -  The subject has a history of substance abuse (including alcohol, drug or other&#xD;
             psychoactive substance) within 1 year before screening.&#xD;
&#xD;
          -  Women who were pregnant, breast-feeding, or serum-HCG(+) on screening; or planning to&#xD;
             become pregnant within 3 months after kick-off of clinical trial.&#xD;
&#xD;
          -  The subject has participated in a drug clinical trial within 1 month before screening.&#xD;
&#xD;
          -  The investigator thinks the subject is unsuitable to enroll in this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huafang LI, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Mental Health Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Anding Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100088</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing HuiLongGuan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Mental Health Center</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Mental Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain Hospital of Jilin Province</name>
      <address>
        <city>Siping</city>
        <state>Jilin</state>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XI'AN Mental Health Center</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>January 19, 2019</last_update_submitted>
  <last_update_submitted_qc>January 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

